Search results for: Multi-Indication Medicines

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

1 July 2018

Using a multidisciplinary methodological approach combining a theoretical economic framework with uptake/market share analyses by country and interviews, this OHE research concludes that: (i) IP incentives for R&D may have…

Issues in Development: a Guide

5 January 1983

…major multinational pharmaceutical companies are working to build up a sensitive understanding of the needs of the poor nations, and of how they can play an appropriate part in meeting…

Value, Affordability, and Decision Making

Value, Affordability, and Decision Making Efficient allocation of healthcare budgets requires a clear understanding of whether interventions deliver good value for money. Resource-allocation decisions should therefore follow structured, transparent, and…

OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development

4 October 2016, 11:00pm

…(Medicines and Healthcare products Regulatory Agency, MHRA, and European Medicines Agency, EMA). Despite these efforts HTA SA is not routinely integrated into the clinical development of new medicines and it…

OHE at AES: Medicines Prices in the UK, Health Inequalities in Costa Rica

25 June 2013

…recent research on projecting medicines expenditures in the NHS using a bottom-up, rather than a top-down, approach. OHE’s participation at the 33rd Meeting of the Spanish Health Economics Association (AES)…

Defining Innovation in Medicines and Transforming it into Value

3 July 2013

…of key European countries to valuing innovation in medicines and explained how actions by payers can affect the rate and direction of innovation. Defining Innovation in Medicines: How to Transform…

Projecting Expenditure on Medicines in the NHS: Second Edition

1 January 2014

…of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time, the PPRS caps future growth in the NHS’s branded medicines bill, between…

Without Prescription: a Study of the Role of Self-Medication

1 July 1968

The total expenditure on medicines in the United Kingdom in 1966 was £267 million. Of this £188 million was for medicines prescribed on the National Health Service. The other £79…

Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience

1 February 2009

Lower usage of cancer medicines in the UK compared to other countries has created questions, including whether the current approach by NICE to assessing cancer medicines is an important factor…